Abivax : Visibilité financière jusqu’au T4 2025 confirmée
>Résultats semestriels sans surprise - La société publie une perte opérationnelle de 80.0 M€ pour le S1 2024 vs une perte de 37.3 M€ l’année dernière. La différence s’explique par des charges d’exploitation en hausse de 47 M€ pour atteindre 86.8 M€ dont une progression de 1/ 32.1 M€ pour la R&D (64.7 M€ au S1 24 vs 32.6 M€ au S1 23) principalement en raison de la progression du programme clinique de phase 3 d’obefazimod dans la RCH, 2/ 4.2 M€ pour les S&M (4.2 M€ vs...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.